Inhigh-risk populations, targeted use of cardiorenal protective agents—includingfinerenone [34], glucagon-like peptide-1 (GLP-1) receptor agonists [35], andsodium-glucose cotransporter-2 (SGLT-2) inhibitors [36]—may attenuate theprogression of atherosclerosis [14, 37]. This evidence concerns the gene SLC5A2 and atherosclerosis.